Lipid derivatives, their production and use

A compound of the formula:

• ##STR43## wherein R.sup.1 is C.sub.10-30 alkyl or a group of the formula R.sup.5 NHCO-- in which R.sup.5 is C.sub.10-30 alkyl;
• R.sup.2 is hydrogen, hydroxy, C.sub.1-5 alkoxy, phenyl-C.sub.1-5 alkoxy, C.sub.1-5 alkanoyloxy, benzoyloxy, phenoxycarbonyloxy, C.sub.1-5 alkoxycarbonyloxy, a group of the formula ##STR44## (in which W is oxygen or sulfur, and R.sup.6 and R.sup.7 are independently hydrogen or C.sub.1-5 alkyl or both, taken together with the adjacent nitrogen atom, form a 3- to 7-membered hetero ring selected from the class consisting of 1-aziridinyl, 1-azetidinyl, 1-pyrrolidinyl, piperidino, 1-perhydroazepinyl, 1-piperazinyl, morpholino, thiomorpholino, 1-perhydrodiazepinyl, 4-perhydrooxazepinyl and 4-perhydrothiazepinyl), amino, C.sub.1-5 alkanoylamino, benzoylamino, optionally oxo-substituted 3- to 7-membered monocyclic amino selected from the class consisting of 1-aziridinyl, 1-azetidinyl, 1-pyrrolidinyl, piperidino, 1-perhydroazepinyl, 1-piperazinyl, morpholino, thiomorpholino, 1-perhydroazepinyl, 1-piperazinyl, morpholino, thiomorpholino, 1-perhydrodiazepinyl, 4-perhydrooxazepinyl and 4-perhydrothiazepinyl, or optionally oxo-substituted 2-isoindolinyl;
• R.sup.3 is C.sub.1-8 alkylene;
• R.sup.4 is hydrogen, C.sub.1-6 alkyl or phenyl-C.sub.1-6 alkyl;
• X is O, S or a group of the formula:
• ##STR45## (in which R.sup.8 is hydrogen, optionally carboxy or C.sub.1-5 alkoxycarbonyl substituted C.sub.1-5 alkyl, C.sub.1-5 alkanoyl, benzoyl, phenoxycarbonyl, C.sub.1-5 alkoxycarbonyl, carbamoyl, mono- or di-C.sub.1-5 alkylcarbamoyl or 3- or 7-membered cyclic aminocarbonyl selected from the class consisting of (aziridin-1-yl)carbonyl, (azetidin-1-yl)carbonyl, (pyrrolidin-1-yl)carbonyl, piperidino-carbonyl, (perhydroazepin-1-yl)carbonyl, (piperazin-1-yl)carbonyl, morpholinocarbonyl and thiomorpholinocarbonyl);
• Y is O, S or a group of the formula ##STR46## (in which R.sup.9 is hydrogen, optionally carboxy or C.sub.1-5 alkoxycarbonyl substituted C.sub.1-5 alkyl, C.sub.1-5 alkanoyl, benzoyl, phenoxycarbonyl, C.sub.1-5 alkoxycarbonyl, carbamoyl, mono- or di-C.sub.1-5 alkylcarbamoyl or 3- to 7-membered cyclic aminocarbonyl selected from the class consisting of (aziridin-1-yl)carbonyl, (azetidin-1-yl)carbonyl, (pyrrolidin-1-yl)carbonyl, piperidino-carbonyl, (perhydroazepin-1-yl)carbonyl, (piperazin-1-yl)-carbonyl, morpholinocarbonyl and thiomorpholinocarbonyl);
• and R.sup.8 and R.sup.9 or R.sup.4 and R.sup.9 may form C.sub.1-4 alkenylene or alkylene unsubstituted or substituted by oxo;
• and
• Z is a nitrogen-containing heterocyclic group selected from the class consisting of azetidinyl, pyrrolidinyl, piperidinyl, perhydroazepinyl, pyrrolinyl, pyrazolinyl, pyrrolyl, pyridyl, oxazolyl, thiazolyl, pyridazinyl, pyrimidyl, pyrazinyl, imidazolyl, morpholinyl, thiomorpholinyl, piperazinyl, pyrazolidinyl, indolyl, isoindolyl, 1H-indazolyl, purinyl, quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydroquinolinyl, perhydroindolyl and perhydroisoquinolinyl, each of said groups being unsubstituted or substituted by optionally hydroxy- or amino-substituted C.sub.1-4 alkyl, hydroxy, amino, imino, mono-or di-C.sub.1-4 alkylamino, carbamoyl, ureido, carboxy, carboxylato or C.sub.1-4 alkoxycarbonyl, wherein a nitrogen atom in said nitrogen-containing heterocyclic group may be converted into a quaternary salt with R.sup.4, wherein R.sup.3 is bound to Z at a position adjacent to the nitrogen atom contained in said nitrogen-containing heterocyclic group represented by Z or a pharmaceutically acceptable salt thereof.